SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD JUN 04
MCX SILVER MAY 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD JUN 04
MCX SILVER MAY 05
MCX CRUDEOIL MAY 19
MCX NATURALGAS APR 27
USD/INR
EUR/INR
GBP/INR
JPY/INR

Closing Bell: Sensex ends 244 points lower, Nifty below 14,300 dragged by IT stocks; broader markets outperform

Asian shares at highest since early March, weak dollar boosts commodities

Oil holds near one-month highs as demand forecasts raised

Rupee rises 23 paise to 74.64 against US dollar in early trade

Oxford University's coronavirus vaccine with AstraZeneca prompts immune response in early test

Updated : July 20, 2020 10:09 PM IST

The experimental vaccine caused minor side effects like fever, chills and muscle pain more often than in those who got a control meningitis vaccine.

Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.

British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked.

In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.

“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.

Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body's T-cells which help to fight off the coronavirus.

The experimental COVID-19 vaccine caused minor side effects like fever, chills and muscle pain more often than in those who got a control meningitis vaccine.

Hill said that larger trials evaluating the vaccine's effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.

How quickly scientists are able to determine the vaccine's effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns.

He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection.

“There's increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart.

Hill said Oxford's vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response.

Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.

“Even 2 billion doses may not be enough,” he said, underlining the importance of having multiple shots to combat the coronavirus.

“There was a hope that if we had a vaccine quickly enough, we could put out the pandemic,” Hill said, noting the continuing surge of infections globally. “I think its going to be very difficult to control this pandemic without a vaccine.”

Numerous countries including Germany, France, the Netherlands, Italy, U.S. and the U.K. have all signed deals to receive hundreds of millions of doses of the vaccine — which has not yet been licensed — with the first deliveries scheduled for the fall. British politicians have promised that if the shot proves effective, Britons will be the first to get it.

In an accompanying editorial, Naor Bar-Zeev and William Moss of the Johns Hopkins Bloomberg School of Public Health called the Oxford results “encouraging" but said further judgment should wait until the vaccine is tested on much bigger populations.

Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.

About a dozen different experimental vaccines are in early stages of human testing or poised to start, mostly in China, the U.S. and Europe, with dozens more in earlier stages of development.

British officials said Monday they had also signed a deal to buy 90 million doses of experimental COVID-19 vaccines being developed by the pharmaceutical giant Pfizer and others.

In a statement, the British government said it had secured access to a vaccine candidate being developed by Pfizer and BioNTech, in addition to another experimental vaccine researched by Valneva.

(With inputs from AP)

Published : July 20, 2020 07:49 PM IST

You May Also Like

Creators throng to Apple's new M1 Macs as they see gains in productivity

Creators throng to Apple's new M1 Macs as they see gains in productivity

In Pics | COVID-19 data highlights for April 20: 2.59 lakh new cases, total death toll climbs to 1.80 lakh

In Pics | COVID-19 data highlights for April 20: 2.59 lakh new cases, total death toll climbs to 1.80 lakh

ACC Q1 Earnings: Low operating costs unlikely to sustain, says Edelweiss Securities

ACC Q1 Earnings: Low operating costs unlikely to sustain, says Edelweiss Securities

Trending on CNBC-TV18

Live TV

recommended for you